Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved ...

Experts discuss the critical unmet needs in HER2-mutant non-small cell lung cancer, highlighting disparities in testing and ...

BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous ...

Regulatory deregulation and liquid biopsy adoption pushing the rapid growth of the oncology companion diagnostic market. In ...

Timely initiation of targeted therapy is crucial for improving cancer outcomes and patient quality of life, especially for ...

The first patient has been dosed in the TROPION-Lung17 phase 3 trial evaluating DATROWAY® (datopotamab deruxtecan) compared ...

Medicaid expansion under the ACA improved long-term survival for younger adults with operable lung cancer, despite no earlier ...

ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why AVBP stock is a Buy.

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

Labcorp added to its suite of tests designed to detect cancer recurrence much earlier than traditional imaging.

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...